ライフサイエンスコーパス: ethambutol

1 butol, followed by 6 months of isoniazid and ethambutol).

2 azid, 25 mg/kg pyrazinamide, and 15-20 mg/kg ethambutol).

3 nd INH, and 1 was resistant to STR, INH, and ethambutol.

4 ed antibiotic regimen was clarithromycin and ethambutol.

5 ve to isoniazid, rifampin, pyrazinamide, and ethambutol.

6 seful in limiting the side effects seen with ethambutol.

7 larithromycin or azithromycin, rifampin, and ethambutol.

8 r both rifampin and streptomycin and 90% for ethambutol.

9 ve phase), with isoniazid, pyrazinamide, and ethambutol.

10 longer cost-effective given the high cost of ethambutol.

11 ve phase), with isoniazid, pyrazinamide, and ethambutol.

12 recursor of levetiracetam, brivaracetam, and ethambutol.

13 and the activity was partially inhibited by ethambutol.

14 .12 mug/ml), rifampin (0.03 to 0.25 mug/ml), ethambutol (0.25 to 2 mug/ml), levofloxacin (0.12 to 1 m

15 en A consisted of TIW azithromycin and daily ethambutol (15 mg/kg/day), daily rifabutin (300 mg/day),

16 bp); rpsL (streptomycin; 196 bp), and embB (ethambutol; 185 bp).

17 35 mg/kg rifampicin per day with 15-20 mg/kg ethambutol, 20 mg/kg rifampicin per day with 400 mg moxi

18 1.25 microg/ml; D-cycloserine, 25 microg/ml; ethambutol, 20 microg/ml; and rifabutin, 0.5 microg/ml.

19 Regimen B consisted of TIW azithromycin, TIW ethambutol (25 mg/kg/dose), TIW rifabutin (600 mg/dose),

20 In one study, after 7 days of daily ethambutol, 300 mg isoniazid per day was administered to

21 C(max)) below target range were frequent for ethambutol (48% of patients); clarithromycin (56%); and

22 picin 35 mg/kg, isoniazid, pyrazinamide, and ethambutol; 59 to rifampicin 10 mg/kg, isoniazid, pyrazi

23 p blockage reduced the mutation frequency to ethambutol 64-fold.

24 ffectiveness of six months of isoniazid plus ethambutol (6EH), thirty-six months of isoniazid (36H) a

25 to clarithromycin (100%), rifabutin (100%), ethambutol (92%), and sulfamethoxazole or trimethoprim-s

26 imens containing rifampin, pyrazinamide, and ethambutol +/- a FQ for a median of 9.7 months.

27 scovered that treatment of mycobacteria with ethambutol, a front-line tuberculosis (TB) drug, signifi

28 utol were more active than pyrazinamide plus ethambutol, a regimen recommended for latent TB infectio

29 combinations with ethambutol (as compared to ethambutol alone) or as D-cycloserine or biotin covalent

30 sults for isoniazid, rifampin, streptomycin, ethambutol, amikacin, kanamycin, capreomycin, ofloxacin,

31 nicotinylhydrazine (INH)], pyrazinamide, and ethambutol, among other drug therapies.

32 iniA gene is also induced by the antibiotic ethambutol, an agent that inhibits cell wall biosynthesi

33 SP II system, agreement increased to 93% for ethambutol and 100% for streptomycin.

34 5.58 +/- 0.10 days (range, 3 to 9 days) for ethambutol and 5.47 +/- 0.11 days (range, 3 to 9 days) f

35 nce rarely occurs in patients also receiving ethambutol and a rifamycin.

36 The patient was treated with ethambutol and ciprofloxacin with a good response; howev

37 By day 7, resistance to both ethambutol and isoniazid had increased.

38 dose-scheduling studies were performed with ethambutol and log-phase growth Mycobacterium tuberculos

39 in Ag85 antigen production when treated with ethambutol and no change in antigen production when trea

40 Continuation regimens consisted mainly of ethambutol and ofloxacin; mean length of therapy 9 month

41 tuberculosis therapy (rifampicin, isoniazid, ethambutol and pyrazinamide) was initiated upon Mycobact

42 The toxicity of ethambutol and related agents was evaluated in rodent re

43 By testing isolates yielding discrepant ethambutol and streptomycin results with a lower concent

44 eded to evaluate critical concentrations for ethambutol and streptomycin that accurately detect susce

45 ceptibility of Mycobacterium tuberculosis to ethambutol and streptomycin was evaluated by comparing M

46 ce of the susceptibility testing results for ethambutol and streptomycin was poor.

47 Performance, however, may be suboptimal for ethambutol and streptomycin.

48 Treatment of wild-type C. glutamicum with ethambutol and subsequent cell wall analyses resulted in

49 and 93.8% for isoniazid, 91.6% and 94.4% for ethambutol, and 100% and 100% for fluoroquinolones, resp

50 trations of isoniazid, 100% for rifampin and ethambutol, and 95% for streptomycin.

51 ve therapy as per local guidance: ofloxacin, ethambutol, and high-dose isoniazid for 6 months.

52 icillin, amoxicillin, rifampicin, isoniazid, ethambutol, and pyrazinamide and also screen for substit

53 e antitubercular drugs, including isoniazid, ethambutol, and pyrazinamide have also recently been def

54 d-line regimen: daily (5 d/wk) moxifloxacin, ethambutol, and pyrazinamide, supplemented with amikacin

55 eived a 4-mo regimen of isoniazid, rifampin, ethambutol, and pyrazinamide.

56 ituberculous regimen of isoniazid, rifampin, ethambutol, and PZA.

57 o methods was 95, 92, and 83% for isoniazid, ethambutol, and rifampin, respectively.

58 imes-weekly (TIW) regimen of clarithromycin, ethambutol, and rifampin.

59 association of DST results for pyrazinamide, ethambutol, and second-line drugs with treatment outcome

60 sceptibility testing (DST) for pyrazinamide, ethambutol, and second-line tuberculosis drugs.

61 uberculosis isolates to isoniazid, rifampin, ethambutol, and streptomycin was evaluated by comparing

62 Ethambutol appears to block specifically the biosynthesi

63 ask) gene when utilized in combinations with ethambutol (as compared to ethambutol alone) or as D-cyc

64 ve either the oral concomitant levofloxacin, ethambutol, azithromycin, and rifampin (CLEAR) regimen o

65 en combining four antibiotics (levofloxacin, ethambutol, azithromycin, and rifamycin) has shown some

66 Ethambutol causes a decrease in cytosolic calcium, an in

67 tients and treated with the same antibiotic (ethambutol, clofazimine, or rifampin) that had been admi

68 iveness was greatest using a fluoroquinolone/ethambutol combination regimen.

69 at least one streptomycin-isoniazid-rifampin-ethambutol drug or PZA.

70 A standard 6-month regimen that included ethambutol during the 2-month intensive phase was compar

71 loxacin (400 mg per day) was substituted for ethambutol during the intensive phase and was continued,

72 iazid [H], rifampicin [R], pyrazinamide [Z], ethambutol [E]) or the control regimen (RHZE thrice week

73 h as resistance to rifampin (RMP) (6.3%) and ethambutol (EMB) (6.0%).

74 , 90.0% for isoniazid (INH) (36/40), 70% for ethambutol (EMB) (7/10), and 89.1% (57/64) combined.

75 ycin (STR), isoniazid (INH), rifampin (RIF), ethambutol (EMB) (collectively known as SIRE), and pyraz

76 azid (INH), rifampin, streptomycin (SM), and ethambutol (EMB) for 34 Peruvian Mycobacterium tuberculo

77 Ethambutol (EMB) is an important component of multidrug

78 Reproducibility of ethambutol (EMB) susceptibility test results for Mycobac

79 in arabinan biosynthesis entailed the use of ethambutol (EMB), a first-line antituberculosis agent th

80 line drugs, isoniazid (INH), rifampin (RIF), ethambutol (EMB), and pyrazinamide (PZA), were determine

81 ited States-isoniazid (INH), rifampin (RMP), ethambutol (EMB), and pyrazinamide (PZA).

82 of resistance to the anti-tuberculosis drug ethambutol (EMB), are the only known implicated enzymes.

83 Mefloquine (MFQ), moxifloxacin (MXF), and ethambutol (EMB), in combination, were evaluated against

84 The anti-tuberculosis drug, ethambutol (Emb), was previously shown to inhibit the sy

85 NH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB).

86 s are a target of the antimycobacterial drug ethambutol (EMB).

87 e antituberculosis drugs isoniazid (INH) and ethambutol (EMB).

88 The antimycobacterial compound ethambutol [Emb; dextro-2,2'-(ethylenediimino)-di-1-buta

89 Ethambutol exerted only a bacteristatic effect; amoxicil

90 The assay also provides information on ethambutol, fluoroquinolone, and diarylquinoline resista

91 daily rifampin, isoniazid, pyrazinamide, and ethambutol followed by 4 mo of rifampin and isoniazid, w

92 of isoniazid, rifampicin, pyrazinamide, and ethambutol, followed by 6 months of isoniazid and ethamb

93 eived isoniazid, rifampin, pyrazinamide, and ethambutol for 8 weeks, followed by 18 weeks of isoniazi

94 However, exposure to isoniazid or ethambutol, front-line antituberculosis drugs which also

95 sign to receive moxifloxacin (400 mg) versus ethambutol given 5 d/wk versus 3 d/wk (after 2 wk of dai

96 o of rifabutin, isoniazid, pyrazinamide, and ethambutol (given daily, thrice-weekly, or twice-weekly

97 atients in the isoniazid group (85%) and the ethambutol group (80%) than in the control group (92%),

98 or 17 weeks, followed by 9 weeks of placebo (ethambutol group).

99 9%) in the isoniazid group, 111 (17%) in the ethambutol group, and 123 (19%) in the control group.

100 ge points (97.5% CI, 6.7 to 16.1) versus the ethambutol group.

101 lid and liquid mediums for the isoniazid and ethambutol groups, as compared with the control group, r

102 0], 0.25 and 4.25 microg/ml, respectively) = ethambutol > clarithromycin (MIC90, 1 microg/ml) > minoc

103 In dose-effect studies, ethambutol had a maximal early bactericidal activity of

104 The combination of levofloxacin-PZA-ethambutol had intermediate bactericidal activity agains

105 While ethambutol had the greatest bacteriologic efficacy in hu

106 Previous exposure to ethambutol halted isoniazid early bactericidal activity.

107 uberculosis, isoniazid, rifampicin, PZA, and ethambutol (HRZE regimen).

108 pyrazinamide, 3.0%; streptomycin, 6.2%; and ethambutol hydrochloride, 2.2%.

109 an isolate resistant to isoniazid, rifampin, ethambutol hydrochloride, and streptomycin (and rifabuti

110 or 6 months reinforced with pyrazinamide and ethambutol in the first 2 months, given thrice-weekly th

111 Inclusion of pyrazinamide and ethambutol in the regimen (when susceptibility was confi

112 ithromycin plus clofazimine, with or without ethambutol, in a prospective, multicenter, randomized op

113 f M. tuberculosis, and the tuberculosis drug ethambutol inhibits other steps in arabinan biosynthesis

114 ekly therapy with a macrolide, rifampin, and ethambutol is a reasonable initial treatment regimen for

115 Ethambutol is an essential medication in the management

116 Ethambutol is specifically toxic to retinal ganglion cel

117 -regulated upon treatment with isoniazid and ethambutol is the iniBAC operon.

118 The anti-tuberculosis drug ethambutol is thought to target a set of arabinofuranosy

119 Ethambutol is used for the treatment of tuberculosis in

120 cs (isoniazid, rifampicin, pyrazinamide, and ethambutol) is efficient to treat most patients, the rap

121 f 17 clinical isolates of M. tuberculosis to ethambutol, isoniazid, and rifampin were tested by the a

122 a control regimen that included 2 months of ethambutol, isoniazid, rifampicin, and pyrazinamide admi

123 og2 dilutions, were 90, 93, 100, and 94% for ethambutol, isoniazid, rifampin, and streptomycin, respe

124 The visual loss associated with ethambutol may be mediated through an excitotoxic pathwa

125 high level of MAC infection, the addition of ethambutol may only delay resistance.

126 toxicity, and glutamate antagonists prevent ethambutol-mediated cell loss.

127 embC accumulated to produce a wide range of ethambutol minimal inhibitory concentrations (MICs) that

128 examined the emergence of drug resistance to ethambutol monotherapy in pharmacokinetic-pharmacodynami

129 m complex (MAC) and to measure the effect of ethambutol on resistance.

130 provided using antitubercular drugs such as ethambutol or isoniazid known to inhibit the biosynthesi

131 tress caused by these mutations or caused by ethambutol or isoniazid treatment may be relieved by ini

132 vo assays, adult rats were administered oral ethambutol over a 3-month period.

133 floxacin versus 71% (98 of 138) treated with ethambutol (p = 0.97).

134 Ethambutol perturbs mitochondrial function.

135 Combined ethambutol plus clarithromycin did not increase anti-MAC

136 apy with multiple drugs including isoniazid, ethambutol, pyrazinamide, and rifampin increased from 4.

137 DST for ethambutol, pyrazinamide, and second-line tuberculosis d

138 the tools were high, whereas the results for ethambutol, pyrazinamide, and streptomycin resistance we

139 The adjusted odds of treatment success for ethambutol, pyrazinamide, and the group 4 drugs ranged f

140 Ethambutol reduced relapses and emergence of clarithromy

141 h two human trials, which showed that adding ethambutol reduced the frequency of clarithromycin-resis

142 Ethambutol resistance is acquired through the acquisitio

143 orage and transport, signal transduction and ethambutol resistance.

144 m tuberculosis strains selected in vitro for ethambutol resistance.

145 Testing additional ethambutol-resistant and streptomycin-resistant strains

146 On the other hand, CSU20, an ethambutol-resistant clinical isolate, makes a vastly he

147 ulted in reduced or increased sensitivity to ethambutol, respectively.

148 For the 74 isolates evaluated, initial ethambutol results agreed by all three methods for 64 (8

149 Patients received CLARI 500 mg twice daily, ethambutol, rifampin (RMP), or rifabutin (RBT) and initi

150 treated in a randomized fashion with either ethambutol, rifampin, or clofazimine, were tested by thr

151 ceptibility results for isoniazid, rifampin, ethambutol, streptomycin, amikacin, kanamycin, capreomyc

152 s that also matched the purported source for ethambutol, streptomycin, and pyrazinamide.

153 reased the expression of downstream embC, an ethambutol target, resulting in MICs of 8 mug/ml.

154 For instance, ethambutol targets arabinogalactan biosynthesis through

155 Levels of agreement for ethambutol tested at 2.5 and 7.5 micro g/ml were 70 and

156 obial agents, including rifampin, isoniazid, ethambutol, tetracycline, and chloramphenicol.

157 Agents such as isoniazid and ethambutol that work by inhibiting cell wall biosynthesi

158 with isoniazid, rifampin, pyrazinamide, and ethambutol thrice weekly for 8 wk, followed by isoniazid

159 sterilizing (rifampin and pyrazinamide), and ethambutol to help prevent the emergence of drug resista

160 Ethambutol toxicity was therefore studied in rodent reti

161 mate is necessary for the full expression of ethambutol toxicity, and glutamate antagonists prevent e

162 our-drug (isoniazid, rifampin, pyrazinamide, ethambutol) treatment (induction phase) were randomly as

163 Increasing ethambutol use by 5 mo increased culture response by 1.5

164 ; 57% of patients achieved target ratios for ethambutol, versus 42% for clarithromycin, 19% for amika

165 roup (46 vs. 21%; P < 0.001); in particular, ethambutol was more frequently discontinued in the daily

166 In all patients isoniazid, pyrazinamide, and ethambutol were added in standard doses for the second 7

167 with rifampin, streptomycin, isoniazid, and ethambutol were compared to those of the BACTEC 460 meth

168 ifloxacin with pyrazinamide, ethionamide, or ethambutol were more active than pyrazinamide plus etham

169 s concentrations of isoniazid, rifampin, and ethambutol were tested by the agar proportion method and

170 s for isoniazid, rifampin, pyrazinamide, and ethambutol were the same in the HFS-TB as in patients.

171 involved the presence of very low levels of ethambutol, which enables the entry of oligonucleotides

172 In the second group, we replaced ethambutol with moxifloxacin for 17 weeks, followed by 9

173 aration, ranging from 5.50 +/- 0.22 days for ethambutol with the inoculum prepared from a McFarland s

174 ed from a McFarland standard to 8.0 days for ethambutol with the inoculum prepared from a seed bottle